Renalytix Investor Relations Material
Latest events
Q1 2024
Renalytix
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Renalytix Plc
Access all reports
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company's lead product candidate is KidneyIntelX, a non-invasive blood test to predict the risk of rapid decline in kidney function, progression to kidney failure, and comorbidities related to Chronic Kidney Disease (CKD), including acute kidney injury, cardiovascular disease, and anemia.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States